Pre-clinical studies have shown that selinexor, an exportin 1 (XPO1) inhibitor, acts as an effective anti-cancer agent and fosters an anti-inflammatory tumor immune microenvironment without harming endogenous tumor-surveillance mechanisms [7,8]. Here, XPO1 is linked to cancer.